NRG1 and non-small cell lung carcinoma: Moreover, the NCT01966445 trial showed that GSK2849330, an anti-ErbB3 monoclonal antibody, elicited a durable 19-month response in NSCLC patients harboring the CD74-NRG1 fusion.